McKesson Corporation (BVMF:M1CK34)
Brazil
· Delayed Price · Currency is BRL | Market Cap | 504.98B |
| Revenue (ttm) | 2.19T |
| Net Income (ttm) | 23.90B |
| Shares Out | n/a |
| EPS (ttm) | 191.37 |
| PE Ratio | 21.12 |
| Forward PE | 19.28 |
| Dividend | 2.87 (0.28%) |
| Ex-Dividend Date | Feb 27, 2026 |
| Volume | 4 |
| Average Volume | 36 |
| Open | 1,032.08 |
| Previous Close | 1,032.49 |
| Day's Range | 1,025.88 - 1,032.08 |
| 52-Week Range | 956.00 - 1,308.54 |
| Beta | 0.42 |
| RSI | 33.49 |
| Earnings Date | May 7, 2026 |
About McKesson
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialt... [Read more]
Financial Performance
In fiscal year 2025, McKesson's revenue was $359.05 billion, an increase of 16.22% compared to the previous year's $308.95 billion. Earnings were $3.30 billion, an increase of 9.76%.
Financial numbers in USDNews
McKesson Corporation Declares Quarterly Dividend
IRVING, Texas--(BUSINESS WIRE)--The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 82 cents per share of common stock. The dividend will be payable on J...
Is McKesson Stock Still A High-Conviction Compounder?
McKesson's net earnings increased at an average rate of 14.4% over the previous three years, while its earnings per share (EPS) grew by 19.6% annually in that same period. This 5.2% disparity indicate...
McKesson to Sell Stake of Medical-Surgical Unit to Apollo
McKesson said Apollo affiliates agreed to buy a minority ownership interest in its medical-surgical solutions business ahead of the unit's planned spinoff.
McKesson sells minority stake in surgical supplies unit to Apollo Funds for $1.25 billion
McKesson said on Monday it will sell a minority stake in its medical-surgical solutions business to investment firm Apollo Funds for $1.25 billion, as it prepares to spin off the unit through an i...
McKesson Signs Agreement with Apollo Funds for Strategic Minority Interest in Medical-Surgical Solutions
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK), a leading Healthcare Services company, today announced it has entered into a definitive agreement with funds managed by affiliates of ...
McKesson ideaShare 2026 Invites Independent Pharmacists to Learn, Connect and Grow
IRVING, Texas--(BUSINESS WIRE)--Registration is now open for McKesson ideaShare 2026, a premier community pharmacy event for independent pharmacy owners and their teams.
McKesson Transcript: Barclays 28th Annual Global Healthcare Conference
Leadership transition is underway with the CFO retiring after reaffirming guidance and overseeing the MedSurg separation. Strong financial results continue, driven by growth in pharmaceutical distribution, Oncology, and technology solutions, with stable trends in generics and specialty. Strategic focus remains on high-growth platforms and disciplined capital allocation.
McKesson Transcript: Leerink Global Healthcare Conference 2026
CFO Britt Vitalone reflected on consistent performance, specialty growth, and technology innovation, including AI and expanded services. Specialty revenues and MSO integrations are strong, while MedSurg prepares for separation. Operational efficiency and customer focus remain priorities.
McKesson Corporation Announces Fourth Quarter Fiscal 2026 Earnings Release Date and Participation in Upcoming Conferences
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will release its fourth quarter fiscal 2026 financial results after market close on Thursday, May 7, 2026. Chief Executive Officer Bria...
McKesson Announces Planned CFO Transition
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) today announced Britt Vitalone, Executive Vice President and Chief Financial Officer (CFO), has elected to retire after a successful an...
See How Institutional Inflows Make McKesson Fly
McKesson Corporation (MCK) shares up 58% in a year thanks to Big Money.
How McKesson Stock Surged 17% In A Day
McKesson (MCK), a prominent pharmaceutical wholesaler, experienced a stock increase of 17% during a high-volume trading session. The driver for this surge was a strong Q3 earnings report that surpasse...
Trump Ally Mullin Buys 10 Stocks, Including These $5 Billion Companies You've Probably Never Heard Of
Mullin reported the purchase of 10 stocks in a new disclosure, according to the Benzinga Government Trades page. The stock purchases were all made on Jan. 5, 2026, with Mullin reporting two purchases ...
McKesson boosts 2026 profit forecast amid specialty drug growth
McKesson Corporation raised its fiscal 2026 profit forecast on Wednesday, betting on strong growth in its oncology and specialty drug distribution businesses.
McKesson Earnings Call Transcript: Q3 2026
Delivered record revenue and double-digit adjusted EPS growth, driven by Oncology, Biopharma Services, and North American distribution. Raised full-year EPS guidance, completed European exit, and advanced Medical-Surgical separation, with strong cash flow and continued investment in technology.
McKesson Corporation Reports Fiscal 2026 Third Quarter Results and Raises Full Year Adjusted EPS Guidance
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2026 third quarter financial results. Results can be accessed on McKesson's Investor Relations website at inves...
McKesson Corporation Completes Divestiture of Norwegian Operations
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced today that it has closed the transaction to sell its retail and distribution businesses in Norway to NorgesGruppen, a private...
McKesson's Practice Insights Designated as a 2026 Qualified Clinical Data Registry by Centers for Medicare & Medicaid Services
IRVING, Texas--(BUSINESS WIRE)--For the tenth year, CMS named McKesson a Qualified Clinical Data Registry approved to participate in the Merit-based Incentive Payment System.
McKesson Transcript: 44th Annual J.P. Morgan Healthcare Conference
Focused on oncology, biopharma, and technology, the company has delivered strong financial growth and is executing a disciplined portfolio strategy, including the separation of its medical business. Expansion in oncology and specialty areas, robust capital allocation, and resilient pharmacy support underpin long-term growth targets.
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #AI--Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. T...
Final Trades: Lockheed Martin, QXO and McKesson Corporation
CNBC's “Halftime Report” Investment Committee discuss their top stocks to watch for the second half of the day's trading session.
Mckesson Corporation Announces Third Quarter Fiscal 2026 Earnings Release Date
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will release its third quarter fiscal 2026 financial results after market close on Wednesday, February 4, 2026. The company will host a...
McKesson Transcript: Evercore ISI 8th Annual HealthCONx Conference
Strong Q2 results led to raised full-year guidance, with robust growth in oncology, vision, and RxTS platforms. Automation, AI, and platform expansion drive efficiency and margin gains, while the medical business separation and generics strategy support long-term value.
McKesson's Advancing Community Oncology Report Charts a New Era of Innovation for Biopharma and Community Care
IRVING, Texas--(BUSINESS WIRE)--McKesson published its first-ever Advancing Community Oncology Report, a look at the trends influencing community oncology practices across the U.S.